Catalog No.
Product Name
Application
Product Information
Citations
-
IRF4
Frenlosirsen is an antisense oligonucleotide that specifically targets interferon regulatory factor 4 (IRF4). It is utilized in research focused on relapsed or refractory multiple myeloma (RRMM), enabling the examination of therapeutic strategies aimed at modulating this transcription factor. This reagent serves as a valuable tool for understanding the role of IRF4 in tumorigenesis and resistance mechanisms in hematological malignancies. -
IFN alpha-IFNAR Inhibitor
IFN alpha-IFNAR-IN-1 is a small-molecule inhibitor that specifically targets the interaction between interferon-alpha (IFN-α) and its receptor, IFNAR. This compound effectively inhibits IFN-α responses induced by modified Vaccinia virus Ankara (MVA) in murine bone marrow-derived plasmacytoid dendritic cell (pDC) cultures, exhibiting an IC50 of 2-8 μM. It serves as a valuable tool for studying the immune response modulation in various infectious and inflammatory conditions. -
Cyclic Di-nucleotide
2'2'-cGAMP is a synthetic cyclic dinucleotide (CDN) that targets the STING (Stimulator of Interferon Genes) pathway, playing a crucial role in the immune response. It effectively induces the production of interferon-beta (IFN-β), a key cytokine involved in antiviral defense. While 2'2'-cGAMP exhibits a weaker affinity for STING compared to 2'3'-cGAMP, it demonstrates a stronger interaction than other CDNs, making it valuable for research in immunology and therapeutic applications related to immune modulation. -
IFN-RI Fusion Protein
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein that functions by binding to interferon receptors, thereby extending their serum half-life. This enhancement can facilitate prolonged biological activity and efficacy in therapeutic applications. Bifarcept is primarily utilized in research exploring the immune response and potential treatments for various diseases mediated by interferon signaling. -
IFNβ inhibitor
StA-IFN-1 is a selective inhibitor of type I interferon (IFN), specifically targeting the activation of IFNβ with an IC50 of 4.1 μM. This compound is utilized in research exploring the roles of IFNβ in immune responses and associated pathologies. Its inhibitory properties make it a valuable reagent for studying the modulation of inflammatory processes and therapeutic strategies in various disease models. -
IRF5 Inhibitor
YE6144 free base is a selective inhibitor of interferon regulatory factor 5 (IRF5). It effectively suppresses disease progression and is particularly beneficial for maintaining remission in preclinical models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the role of IRF5 in autoimmune disorders and potential therapeutic strategies for SLE. -
IRF3 Inhibitor
Sim-9 is a covalent allosteric inhibitor targeting interferon regulatory factor 3 (IRF3). By binding covalently to the Cys222 residue, Sim-9 induces a conformational change that inhibits interactions between IRF3 and key signaling partners such as TRIF, MAVS, and STING, ultimately blocking homodimerization and the type I interferon response. This compound demonstrates significant anti-inflammatory and organ-protective effects in mouse models of sepsis and acute pancreatitis, making it a valuable tool for research focused on inflammatory diseases. -
NK Cell Activator
Antitumor agent-210 is an NK cell activator known for enhancing the activation and degranulation of natural killer (NK) cells. It exerts a modest proliferative effect on NK92 cells, significantly increasing their cytotoxicity against tumor cells. This compound promotes the release of key cytokines, including granzyme B, perforin, and IFN-γ, and has demonstrated efficacy in reducing lung metastatic lesions in murine models. Antitumor agent-210 is a valuable reagent for researching melanoma lung metastasis and other cancer-related immunological studies. -
IFNAR Inducer
CP-28888 is an interferon alpha/beta receptor (IFNAR) inducer that enhances the immune response by promoting the production of type I interferons. It exhibits greater potency in murine models, making it a valuable tool for studying immune modulation and antiviral responses in preclinical research. Despite its limited efficacy in human trials and lack of antirhinovirus activity, CP-28888 remains a relevant compound in the investigation of therapeutic approaches targeting interferon pathways. -
IKZF2 degrader
NVP-DKY709 is an orally active molecular glue degrader targeting IKZF2. This compound demonstrates a Dmax of 53% and a DC50 of 4 nM, indicating potent degradation efficacy. Additionally, NVP-DKY709 can also degrade IKZF4 and SALL4 with DC50 values of 13 nM and 2 nM, respectively. Its mechanism involves binding to CRBN, altering its conformation to facilitate the recruitment and degradation of IKZF2, thereby exerting significant anti-tumor activity. This functionality positions NVP-DKY709 as a valuable tool in cancer research and therapeutic development targeting IKZF protein family members. -
PROTAC IKZF1/3 Degrader
Cemsidomide is a PROTAC degrader targeting IKZF1 and IKZF3, utilizing the ubiquitin ligase pathway. It exhibits potent biological activity with a GI50 of 0.05 nM against NCIH929.1 cells. This compound is primarily employed in the exploration of multiple myeloma (MM) research, facilitating the study of targeted protein degradation in cancer therapeutics. -
IKZF2 Molecular Glue Degrader
PLX-4545 is an orally active and selective molecular glue degrader that targets IKZF2 (zinc finger transcription factor Helios) via cereblon. This compound reprograms immunosuppressive regulatory T cells into pro-inflammatory effector T cells, thereby enhancing anti-tumor immune responses. PLX-4545 is intended for research applications related to solid tumors and the modulation of T cell functionality. -
IKZF2 Molecular Glue Degrader
(S,S)-PLX-4545 is a cereblon-based molecular glue degrader targeting IKZF2, a zinc finger transcription factor involved in immune regulation. This compound effectively promotes the degradation of IKZF2, making it a valuable tool for investigating IKZF2-related diseases, including various proliferative disorders and cancers. Researchers can leverage (S,S)-PLX-4545 to explore therapeutic strategies targeting IKZF2 functionality in different biological contexts. -
Enantiomer Of PLX-4545
(1S,2S,3R)-PLX-4545 is the (1S,2S,3R) enantiomer of PLX-4545, functioning as a selective cereblon-based molecular glue degrader that targets IKZF2 (zinc finger transcription factor Helios). This compound effectively reprograms immunosuppressive regulatory T cells into pro-inflammatory effector T cells, enhancing anti-tumor immune responses. Its applications extend to immunology and cancer research, providing insights into T cell modulation and potential therapeutic strategies for cancer immunotherapy. -
IKZF2 Selective and orally Inhibitor
PVTX-405 is a selective, orally bioavailable inhibitor targeting IKZF2, designed as a molecular glue degrader. With a DC50 of 0.7 nM and a Dmax of 91%, it enhances degradation efficiency while minimizing off-target effects, exhibiting an IC50 of 48 µM for hERG inhibition. PVTX-405 demonstrates significant antitumor activity by inhibiting the growth of MC38 tumors and shows improved efficacy when combined with immune checkpoint therapies, such as anti-PD1 or anti-LAG3, in mouse models. -
IKAROS Protein Degrader
MGD-4 is an orally bioavailable IKAROS protein degrader that operates via Cereblon (CRBN) dependence, demonstrating effective degradation of IKZF1 (DC50=67.2 nM), IKZF2 (DC50=918.2 nM), and IKZF3 (DC50=95.8 nM). It exhibits significant anti-proliferative activity against multiple myeloma, making it a valuable tool for research into therapies targeting hematological malignancies. This compound is ideal for studies investigating the role of IKAROS family proteins in cancer biology and the development of protein degradation strategies. -
USP3 ZnF-UBD Ligand
USP3 ZnF-UBD Ligand-1 is a small molecule that specifically targets the zinc finger ubiquitin-binding domain (ZnF-UBD) of USP3, exhibiting a binding affinity characterized by a KD of 14 μM. This ligand can be utilized in studies investigating the role of USP3 in ubiquitin signaling pathways and its implications in various diseases. Its ability to selectively bind to USP3 enables researchers to explore potential therapeutic strategies targeting this deubiquitinating enzyme. -
Molecular Glue IKZF2-Degrader
IKZF2-degrader 3 is a molecular glue that selectively targets and degrades the IKZF2 protein, exhibiting a DC50 of 2.0 nM. It enhances the understanding of IKZF2's role in various biological processes and is useful for studying its implications in hematological malignancies. This reagent is valuable for research focused on targeted protein degradation and its therapeutic potential in cancer treatment. -
IKZF1 Degrader
IKZF1-degrader-2 is a molecular glue degrader that specifically targets IKZF1, facilitating its degradation in cancer cells. This compound exhibits potent anticancer activity while demonstrating low toxicity, making it a valuable tool for oncology research. IKZF1-degrader-2 is ideal for studies focused on targeted protein degradation and its therapeutic implications in cancer treatment. -
IKZF2 Degrader
IKZF2-degrader 2 is a selective molecular glue degrader that targets IKZF2, facilitating its ubiquitination and subsequent degradation through recruitment of the CRL4-CRBN E3 ubiquitin ligase. With DC50 values of 0.5 nM and 1.8 nM in HiBit and FACS assays, respectively, this compound also induces moderate degradation of SALL4 (DC50 of 9 nM) without significantly affecting IKZF1, IKZF3, CK1α, or GSPT1. IKZF2-degrader 2 is suitable for investigating mechanisms in cancer immunology. -
IKZF2 Molecular Glue Degrader
IKZF2-degrader 1 is a selective IKZF2 molecular glue degrader that exhibits a DC50 of 0.5 nM, effectively targeting IKZF2 for degradation. With minimal activity against CK1α (DC50: 210 nM), it provides a focused approach for studying the role of IKZF2 in cellular processes. This compound is valuable for researching IKZF2-dependent cancers, enabling investigations into its therapeutic potential and biological mechanisms. -
PROTAC Target Protein Ligand
IKZF1/3 ligand-1 is a PROTAC target protein ligand designed for the synthesis of PROTACs, specifically the PROTAC IKZF1/3 Degrader-1. This compound exhibits potent degradation activity against IKZF1 and IKZF3, making it a valuable tool in neuroprotective research applications. Its mechanism supports the targeted degradation of IKZF proteins, facilitating studies into their roles in various biological processes and disease pathways. -
IKZF2 Degrader
IKZF2-degrader 4 is an IKZF2-targeting compound that facilitates the degradation of the IKZF2 protein. Through its mechanism, this degrader can disrupt the function of IKZF2, which is implicated in various cancer pathways. It is a valuable tool for investigating IKZF2's role in tumor biology and for exploring therapeutic strategies in cancer research. -
IKZF1 Degrader
IKZF1-degrader-1 is a molecular glue degrader targeting IKZF1, with a DC50 value of 0.134 nM. This compound facilitates the selective degradation of IKZF1, making it a valuable tool for research into tumor biology and potential cancer therapies. Its ability to modulate IKZF1 levels may provide insights into the role of this transcription factor in oncogenesis and therapeutic resistance. -
Uveitis-inducing Epitope
IRBP (651-670) human, mouse is an epitope derived from the conserved region of interphotoreceptor retinoid binding protein (IRBP), functioning primarily as a uveitis-inducing agent. This specific fragment has been shown to elevate levels of pro-inflammatory cytokines, including IL-1β, IL-6, TNFα, IL-17A, and IL-17F, within ocular tissues. Due to its conservation across human, mouse, and bovine species, IRBP (651-670) is valuable in the study of experimental autoimmune uveitis and related inflammatory processes in ocular research. -
IDE/NLRP3 Inhibitor
ML345 is a selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, exhibiting an IC50 of 188 nM for IDE. By targeting the Cys819 residue, ML345 effectively inhibits IDE activity, while it binds non-covalently to NLRP3, modulating its function. This compound is known to inhibit the release of inflammatory cytokines such as IL-1β and IL-6, demonstrating significant anti-inflammatory properties. Additionally, ML345 has been shown to provide protective effects against miscarriage, making it a valuable tool for research in inflammation and reproductive health. -
Fas receptor Antagonist
Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions. -
Interleukin-2 Derivative
Dazupegleukin is an interleukin-2 derivative that functions primarily as an immunomodulator. It exhibits antineoplastic properties, making it a valuable candidate for research focused on cancer immunotherapy. The compound can enhance T-cell proliferation and activation, thus playing a significant role in studies aimed at understanding and manipulating immune responses against tumors. Its applications extend to exploring novel therapeutic strategies in oncology. -
HDAC3 Degrader
HDAC3 Degrader-2 is a selective degrader of histone deacetylase 3 (HDAC3), functioning through targeted degradation to inhibit the activation of the NLRP3 inflammasome. By facilitating the reduction of IL-1β maturation and caspase-1 activity, HDAC3 Degrader-2 demonstrates significant anti-inflammatory effects. This reagent is applicable in researching conditions such as endotoxin shock, colitis, and gouty arthritis, providing valuable insights into mechanisms of inflammation and therapeutic interventions. -
KLK5 Inhibitor
Kallikrein 5-IN-2 is a selective inhibitor of Kallikrein 5 (KLK5), exhibiting a pIC50 of 7.1. This compound demonstrates the ability to regulate epidermal shedding, potentially alleviating related inflammation and pruritus. Kallikrein 5-IN-2 serves as a valuable tool in research focused on dermatological conditions and the modulation of skin barrier function. -
Plasma Kallikrein Inhibitor
Sebetralstat is a selective inhibitor of plasma kallikrein, a serine protease involved in the kallikrein-kinin system. This compound demonstrates significant activity in modulating bradykinin levels, making it relevant for investigating metabolic diseases and conditions associated with dysregulated kallikrein activity. Its ability to inhibit plasma kallikrein positions Sebetralstat as a valuable tool for research into therapeutic strategies for associated pathologies. -
Coagulation Factor XII/Kallikrein Inhibitor
D-Pro-Phe-Arg-Chloromethylketone is a selective inhibitor of coagulation factor XII and plasma kallikrein. This compound is essential for studying the mechanisms of thrombosis and inflammation, making it a valuable tool for research in cardiovascular diseases and related fields. Its ability to inhibit these factors can provide insights into the regulation of hemostasis and the inflammatory response. -
Plasma Kallikrein Inhibitor
KVD-001 is a potent inhibitor of plasma kallikrein, a serine protease involved in the kallikrein-kinin system. This compound demonstrates significant biological activity by modulating vascular permeability and inflammatory responses. KVD-001 is applicable in research focused on diabetic macular edema, providing valuable insights into therapeutic interventions for ocular diseases. -
Tissue Kallikrein Inhibitor
FE-999024 is a selective inhibitor of tissue kallikrein, a serine protease involved in various physiological processes. This compound has demonstrated the ability to reduce cancer cell invasion by up to 39% and to decrease eosinophilia in models of allergic inflammation. FE-999024 serves as a valuable tool in research focused on cancer, inflammation, and immunology, contributing to a deeper understanding of these biological pathways. -
Plasma Kallikrein Inhibitor
Berotralstat is an orally active plasma kallikrein inhibitor that demonstrates significant potential in the modulation of vascular permeability. By inhibiting plasma kallikrein, Berotralstat has been shown to reduce brain edema, making it a valuable candidate for research in glioblastoma and hereditary angioedema. Its application in these areas may contribute to improved therapeutic strategies for conditions characterized by excessive vascular leakage and inflammation. -
Substrate for Kallikrein
D-Val-Leu-Arg-pNA acetate serves as a substrate for the serine protease kallikrein. It enables the assessment of kallikrein activity through the release of p-nitroaniline upon peptide cleavage. This compound is valuable for research applications focused on the role of kallikrein in various physiological and pathological processes, providing insights into its functions in inflammation and fluid regulation. -
Plasma Kallikrein Inhibitor
PKSI-527 is a highly selective plasma kallikrein inhibitor that targets the kallikrein-kinin system. It demonstrates significant potential in suppressing collagen-induced arthritis (CIA) by modulating inflammatory responses. PKSI-527 serves as a valuable tool for studying the role of plasma kallikrein in various pathological conditions and may aid in the development of therapeutic strategies for rheumatoid arthritis. -
Kallikrein Inhibitor
Feniralstat is a potent kallikrein inhibitor that exhibits an IC50 of 6.7 nM for human plasma kallikrein (pKal). This pyrazole derivative demonstrates selectivity, showing no inhibition on human KLKl, human FXIa, or human Factor XIIa, with IC50 values greater than 40 μM. Feniralstat is a valuable tool for investigating kallikrein-related pathways and may have implications in research focused on coagulation and inflammatory processes. -
Plasma Kallikrein Inhibitor
Berotralstat dihydrochloride is an orally active inhibitor of plasma kallikrein, a serine protease involved in the Bradykinin pathway. This compound has demonstrated efficacy in reducing brain edema and is under investigation for its therapeutic potential in glioblastoma and hereditary angioedema. Research applications include the study of inflammatory pathways and the modulation of vascular permeability in various disease states. -
Kallikrein Inhibitor
PPACK II diTFA is an irreversible inhibitor targeting glandular and plasma kallikreins. It demonstrates specificity in modulating kallikrein activity, making it a valuable tool for studies focused on coagulation, inflammation, and related pathways. This compound is essential for research exploring the physiological roles of kallikreins and their potential implications in various diseases. -
Plasma Kallikrein Inhibitor
Plasma kallikrein-IN-4 is a selective inhibitor of plasma kallikrein, exhibiting an IC50 of 0.016 μM against human plasma kallikrein. This compound effectively modulates the kallikrein-kinin system, contributing to its potential as a therapeutic agent in conditions associated with dysregulated bradykinin signaling. Plasma kallikrein-IN-4 is valuable for research applications focusing on cardiovascular diseases, inflammation, and pain signaling pathways. -
Kallikrein Inhibitor
LSP-249 is a potent plasma kallikrein inhibitor with an EC50 of less than 100 nM in cellular assays. This compound is currently being investigated for its therapeutic potential in treating angioedema. Its ability to modulate kallikrein activity makes it a valuable tool for research focused on vascular permeability and related disorders. -
Prekallikrein Inhibitor
Donidalorsen sodium is an antisense oligonucleotide that selectively targets prekallikrein (PKK). By binding to and promoting the degradation of PKK mRNA in the liver, Donidalorsen sodium effectively inhibits kallikrein activity and diminishes Bradykinin production. This reagent is particularly valuable for research applications related to hereditary angioedema. -
Kallikrein 5 Inhibitor
Eflumenibep alfa is a Kallikrein 5 inhibitor that exhibits anti-inflammatory properties. This fusion protein consists of human SPINK2 linked to the human IgG1 Fc fragment at the C-terminus, enabling it to effectively modulate inflammatory pathways. It is primarily used in research applications focused on inflammatory diseases and conditions related to kallikrein signaling. -
KLK6 Inhibitor
DKFZ-633 is a potent inhibitor of KLK6, exhibiting an IC50 of 250 nM against human KLK6. This compound covalently labels active KLK6 with high specificity, enabling the efficient pull-down and capture of endogenous KLK6 from cell-conditioned media. DKFZ-633 is an essential reagent for studying the role of KLK6 and its regulatory mechanisms, particularly in the context of head and neck cancer research. -
Plasma Kallikrein (pKal) Inhibitor
pKal-IN-1 is a selective inhibitor of plasma kallikrein (pKal), an enzyme involved in the kallikrein-kinin system, which plays a significant role in inflammatory processes. This compound has demonstrated the ability to modulate vascular permeability and inflammation, making it a valuable tool for studying diabetic macular edema and diabetic retinopathy. pKal-IN-1 can be utilized in various research applications aimed at understanding the therapeutic potential in treating these diabetes-related ocular conditions. -
Kallikrein Inhibitor
Ecallantide is a specific inhibitor of plasma kallikrein, effectively reducing the production of bradykinin. Its primary biological activity lies in the prevention of acute angioedema attacks, making it a valuable tool for research into conditions related to excessive bradykinin activity. Ecallantide is applicable in studies focusing on inflammatory responses and therapeutic interventions for angioedema disorders. -
Kallikrein Inhibitor
PPACK II is a potent irreversible inhibitor of glandular and plasma kallikreins, targeting their enzymatic activity. This compound is essential for studying the physiological roles of kallikreins in various biological processes, including inflammation and pain modulation. It is valuable for research applications focused on understanding kallikrein-related pathways and developing therapeutic strategies for associated diseases. -
Kallikrein-5 Inhibitor
GSK951 is a potent and selective inhibitor of Kallikrein-5 (KLK5), demonstrating an IC50 of 250 pM with over 100-fold selectivity against KLK7 and KLK14. This compound is designed for effective epidermal delivery and has been shown to reduce transepidermal water loss while decreasing pro-inflammatory cytokine expression. GSK951 is valuable for research applications in inflammation and immunology, particularly in studies related to Netherton syndrome. -
Kallikrein Inhibitor
Feniralstat hydrochloride is a potent inhibitor of kallikrein, with an IC50 value of 6.7 nM for human plasma kallikrein (pKal). This pyrazole derivative exhibits selectivity, showing no significant inhibition on human Kallikrein KLKl, FXIa, or Factor XIIa (IC50 values greater than 40 μM). Feniralstat is useful in research applications studying kallikrein's role in various biological processes and disease states, particularly in conditions associated with dysregulated kallikrein activity.
